NanoViricides FY26 net loss narrows 13% to $8.22 million
The company reported no revenue for the year ended June 30, 2026. Basic and diluted loss per share improved to $0.41 from $0.63, while cash and cash equivalents were $2.8 million.
The company reported no revenue for the year ended June 30, 2026. Basic and diluted loss per share improved to $0.41 from $0.63, while cash and cash equivalents were $2.8 million.